Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting-Reference-Cited by-全球学者库

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Published:2021-09-16 Issue:12 Volume:385 Page:1078-1090
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Barda Noam¹,Dagan Noa¹^ORCID,Ben-Shlomo Yatir¹,Kepten Eldad¹,Waxman Jacob¹,Ohana Reut¹,Hernán Miguel A.¹^ORCID,Lipsitch Marc¹^ORCID,Kohane Isaac¹,Netzer Doron¹,Reis Ben Y.¹,Balicer Ran D.¹

Affiliation:

1. From the Clalit Research Institute, Innovation Division (N.B., N.D., Y.B.-S., E.K., J.W., R.O., R.D.B.), and the Community Medical Services Division (D.N.), Clalit Health Services, Tel Aviv, and Software and Information Systems Engineering (N.B., N.D.) and the School of Public Health, Faculty of Health Sciences (R.D.B.), Ben-Gurion University of the Negev, Be’er Sheva — both in Israel; the Department of Biomedical Informatics (N.B., N.D., I.K.), and the Ivan and Francesca Berkowitz Family Living...

Funder

Morris–Singer Foundation

The Ivan and Francesca Berkowitz Family Precision Medicine Clinic at Clalit Research Institute

Ivan and Francesca Berkowitz Family Living Laboratory at Harvard Medical School

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2110475

Cited by 728 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myocarditis and Pericarditis;Primary Care: Clinics in Office Practice;2024-03

2. Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis;Vaccines;2024-02-06

3. Risk of Herpes Zoster Ophthalmicus After COVID-19 Vaccination in a Large US Health Care Claims Database;American Journal of Ophthalmology;2024-02

4. Safeguarding COVID-19 Vaccines: Establishing the Safety of Novel Vaccine Platforms;Clinical Microbiology and Infection;2024-02

5. Real-World Effectiveness of a Third Dose of mRNA-1273 versus BNT162b2 on Inpatient and Medically Attended COVID-19 among Immunocompromised Adults in the United States;2024-01-31